RESEARCH COMMUNICATIONS OF THE 28th ECVIM-CA CONGRESS

In dogs with stages I/II surgically treated (n=12), recurrence occurred at a median disease‐free survival time (DFS) of 20±49days (n=6); in the remaining 6 dogs recurrence was not observed until death. Among dogs with stages III/IV (n=11), the median overall survival time (OST) in TG was significantly higher (282±73days) than the median OST of dogs in CG (59±18days) (p=0.020). In TG, a stable disease (n=5) and partial response (n=1) was observed at 180 days of treatment. Toceranib phosphate was maintained until progressive disease (n=1) or severe adverse effects (n=4) occurred. Grade 1 and 2 (n=3) gastrointestinal signs occurred initially (3‐4 weeks), and Grade 4 (n=4) after months causing treatment withdrawal.